Arcutis Biotherapeutics, Inc.
NASDAQ:ARQT
8.72 (USD) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Arcutis Biotherapeutics, Inc. |
Symbool | ARQT |
Munteenheid | USD |
Prijs | 8.72 |
Beurswaarde | 1,019,289,520 |
Dividendpercentage | 0% |
52-weken bereik | 1.76 - 13.17 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Todd Franklin Watanabe M.A. |
Website | https://www.arcutis.com |
An error occurred while fetching data.
Over Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)